The world of evidence is changing, with regulators and payers increasingly seeking the demonstration of value beyond clinical outcomes. YOLARX provides below a selection of guidelines and guidance documents established by international pharmacoepidemiology societies or organisations and regulators. They are listed in order of appearance with the most recent publication on top.

YOLARX has created these links for educational and research purposes only, and cannot take responsibility for content of third party web sites. Inclusion of a link does not imply endorsement of or association with YOLARX.

Pharmacoepidemiology and clinical studies:


Pharmacovigilance and risk management:


Systematic reviews and meta-analyses:

  • PRISMA for Systematic Review Protocols (PRISMA-P): Moher D, et al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1; last accessed on 01 November 2022


Rapid & scoping reviews:

  • Cochrane Recommendations for Rapid Reviews (2020); Garritty C, et al. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol. 2021 Feb;130:13-22. doi: 10.1016/j.jclinepi.2020.10.007. Epub 2020 Oct 15; last accessed on 01 November 2022